Company news
IN8bio, Inc. news in 2022
IN8bio, Inc.'s news releases, calls and decks from 2022, newest first.
IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100
December 11, 2022
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
December 7, 2022
IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 9, 2022
IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400
September 14, 2022
IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board
September 7, 2022
IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering
August 18, 2022
IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock
August 15, 2022
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022
IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock
August 10, 2022
IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients
July 26, 2022
Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform
July 20, 2022
IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development
July 11, 2022
IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences
June 7, 2022
IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022
June 5, 2022
IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform
May 16, 2022
IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022
IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting
May 4, 2022
IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments
April 12, 2022
IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
March 27, 2022
IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
March 16, 2022
IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme
January 5, 2022